Date Insider Type Main position Quantity % Market Cap.
23/10/23 Free

General Counsel

70,000 0.7479%
16/10/23 Free

Chief Financial Officer

151,416 1.6178%
15/09/23
Versi Group LLC
ConversionCompany 729,200 7.7913%
Change 5-day change 1-year change 3-year change Capi.($)
-99.00%-99.00% - - 10
-3.97%-1.67%+53.42%+156.54% 1,079B
-3.61%-1.13%+53.25%+53.01% 640B
-1.91%+0.51%+36.41%+72.64% 465B
-2.29%+1.12%+36.13%+30.60% 353B
-2.28%-0.69%+33.42%+39.21% 301B
-3.15%+0.25%+10.63%+13.71% 271B
-2.12%+3.31%+1.82%-39.41% 228B
-0.76%+3.39%+27.45%+64.04% 209B
-2.17%-0.73%+13.19%+70.61% 165B
Average -12.14%+4.83%+29.53%+51.22% 412.19B
Weighted average by Cap. -2.93%+4.86%+38.45%+75.20%
Logo DMK Pharmaceuticals Corporation
DMK Pharmaceuticals Corporation is a commercial stage neuro-biotech company. The Company is focused on developing and commercializing products for the treatment of opioid overdose and substance-use disorders. Its ZIMHI (naloxone) is FDA approved for the treatment of opioid overdose. It is focused on developing novel therapies for opioid use disorder (OUD) and other important neuro-based conditions where patients are currently underserved. Its technologies are at the forefront of endorphin-inspired drug design with its mono, bi-, and tri-functional small molecules that simultaneously modulate critical networks in the nervous system. It has a library of approximately 750 small molecule neuropeptide analogues and a differentiated pipeline. The Company’s lead clinical-stage product candidate, DPI-125, is being studied as a treatment for OUD. Its other development stage product candidates include DPI-221 for bladder control problems and DPI-289 for severe end stage Parkinson’s disease.
Employees
12
  1. Stock Market
  2. Stocks
  3. DMKPQ Stock